Hillenbrand Fiscal Q1 Adjusted Earnings, Revenue Fall; Agrees to Sell 51% Stake in Milacron Business

MT Newswires Live
06 Feb

Hillenbrand (HI) reported fiscal Q1 adjusted diluted earnings late Wednesday of $0.56 per share, down from $0.69 a year earlier.

Analysts polled by FactSet expected $0.54.

Net revenue for the quarter ended Dec. 31 was $706.9 million, down from $773.3 million a year earlier.

Analysts surveyed by FactSet expected $695.4 million.

Meanwhile, the company said it agreed to sell a 51% stake in its Milacron injection molding and extrusion business for $287 million to an affiliate of Bain Capital.

Net proceeds after tax are expected to be about $250 million and will be used for debt paydown. The deal is expected to close at the end of Hillenbrand's fiscal Q2 or beginning of fiscal Q3, the company said.

Hillenbrand updated its fiscal 2025 outlook to account for the sale. It now expects fiscal 2025 adjusted earnings of $2.45 to $2.80 per share on revenue of $2.63 billion to $2.79 billion. The company's previous guidance was $2.80 to $3.15 per share on revenue of $2.93 billion to $3.09 billion.

Analysts polled by FactSet expect adjusted earnings of $2.95 per share on revenue of $3.01 billion.

Hillenbrand also issued its fiscal Q2 adjusted earnings guidance of $0.53 to $0.58 per share on revenue of $685 million to $705 million. Analysts surveyed by FactSet expect $0.64 and $730.8 million, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10